The Tumor Lysis Syndrome
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An important consideration with respect to safety in patients that may have a compromised immune system is that engineered bacterial products are likely to engage both innate and adaptive immunity in the event of release of the organism into the body following tumor lysis75, triggering inflammatory responses.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Self-citationCairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationOral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Cited by
Items 101–200 of 1,000
Diagnosis and Management of Oncologic Emergencies
Klemencic, S., & Perkins, J. (2019) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2018.12.37335 · Cited by 67
Fischer, K., Al‐Sawaf, O., & Hallek, M. J. (2020) · Hematology · doi:10.1182/hematology.2020000120 · Cited by 67
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Qin, X., Ning, W., Liu, H., Liu, X., Luo, W., & Xia, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.027 · Cited by 66
Sands, J. M., Champiat, S., Hummel, H.-D., Paulson, K. G., Borghaei, H., Alvarez, J. B., Carbone, D. P., Carlisle, J. W., Choudhury, N. J., Clarke, J. M., et al. (2025) · Cancer · doi:10.1002/cncr.35738 · Cited by 66
Anaphylactic Reactions to Oligosaccharides in Red Meat: a Syndrome in Evolution
Saleh, H., Embry, S., Nauli, A. M., Atyia, S., & Krishnaswamy, G. A. (2012) · Clinical and Molecular Allergy · doi:10.1186/1476-7961-10-5 · Cited by 66
“Non-IgE reactions may be secondary to cytokine release and/or tumor lysis syndrome [80-84].”
BackgroundWang, M. L., Jurczak, W. J., Trněný, M., Belada, D., Wróbel, T., Ghosh, N., Keating, M., van Meerten, T., Alvarez, R. F., von Keudell, G., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00682-x · Cited by 66
Crane, J. K. (2013) · Gut Microbes · doi:10.4161/gmic.25584 · Cited by 65
“Although our experimental study dealt primarily with EPEC and diseases such as gout or tumor lysis syndrome.(5) We examined whether uric acid crystals ever formed in intestinal tissues or in the lumen of the gut as well as in the joints of gout sufferers.”
BackgroundLou, J. W. H., Aragaki, M., Bernards, N., Chee, T., Gregor, A., Hiraishi, Y., Ishiwata, T., Leung, C., Ding, L., Kitazawa, S., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121918 · Cited by 65
Howard, S. C., Avagyan, A., Workeneh, B., & Pui, C. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00542-w · Cited by 64
“Importantly, these criteria exclude manifestations directly attributable to other causes, such as a patient with a known seizure disorder whose seizures are unlikely to have been caused by hypocalcaemia 2 .”
InfluentialSelf-citationToxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 62
Nephrotoxicity after radionuclide therapies
Parihar, A. S., Chopra, S., & Prasad, V. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101295 · Cited by 61
“This metabolic imbalance can lead to renal insufficiency, cardiac arrhythmias, seizures and can culminate with death due to multi-organ failure [45].”
BackgroundEarly Complications of Hyperleukocytosis and Leukapheresis in Childhood Acute Leukemias
Abla, O., Angelini, P., Giuseppe, G. D., Kanani, M. F., Lau, W., Hitzler, J. K., Sung, L., & Naqvi, A. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000490 · Cited by 59
Diagnosis and management of tumor lysis syndrome.
Puri, I., Sharma, D. R., Gunturu, K. S., & Ahmed, A. A. (2020) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1761185 · Cited by 58
Perissinotti, A. J., Bishop, M. R., Bubalo, J. S., Geyer, M. B., Goodrich, A., Howard, S. C., Kula, J., Mandayam, S. A., Cairo, M. S., & Pui, C. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102603 · Cited by 57
Self-citationDark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation
Jiang, M., Gu, D.-N., Dai, J., Huang, Q., & Tian, L. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.018 · Cited by 57
Ichaï, C., Vinsonneau, C., Souweine, B., Armando, F., Canet, E., Clec’h, C., Constantin, J., Darmon, M., Duranteau, J., Gaillot, T., et al. (2016) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2016.03.004 · Cited by 57
Wang, M. L., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W. J., Wu, K. L., Bishton, M. J., Collins, G. P., Eliadis, P. E., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01188-x · Cited by 58
Tumour and microparticle tissue factor expression and cancer thrombosis
Date, K. L., Hall, J., Greenman, J., Maraveyas, A., & Madden, L. A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.013 · Cited by 56
Venetoclax: Targeting BCL2 in Hematological Cancers
Scheffold, A., Jebaraj, B. M. C., & Stilgenbauer, S. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_11 · Cited by 57
“Prophylaxis and treatment of TLS includes hydration, diuresis, monitoring of electrolytes, and prevention of hypouricemia with allopurinol or rasburicase (Howard et al. 2011).”
BackgroundSpontaneous tumour lysis syndrome
Kekre, N. K., Djordjevic, B., & Touchie, C. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.111251 · Cited by 55
“3,4,6 First, the risk is related to the malignancy itself.”
BackgroundMethodTumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency
Criscuolo, M., Fianchi, L., Dragonetti, G., & Pagano, L. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1127156 · Cited by 55
“out.[2,17,18] First, the type of cancer itself is a strong predictor of spontaneous and therapy related cell lysis.”
BackgroundAgents for the Treatment of Gout: Current Advances and Future Perspectives
Zeng, X., Liu, Y., Fan, Y., Wu, D., Meng, Y., & Qin, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01710 · Cited by 54
Harvey, D. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s62512 · Cited by 54
CAR T-cell therapy and critical care: A survival guide for medical emergency teams
Messmer, A. S., Que, Y., Schankin, C. J., Banz, Y., Bacher, U., Novak, U., & Pabst, T. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01948-2 · Cited by 54
Buhtoiarov, I. N. (2017) · Pediatrics in Review · doi:10.1542/pir.2016-0152 · Cited by 54
Hyperleukocytosis: Emergency Management
Jain, R., Bansal, D., & Marwaha, R. K. (2012) · The Indian Journal of Pediatrics · doi:10.1007/s12098-012-0917-3 · Cited by 54
Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases
Alqurashi, R. M., Tamim, H. H., Alsubhi, Z. D., Alzahrani, A., & Tashkandi, E. M. (2022) · Cureus · doi:10.7759/cureus.30652 · Cited by 53
“We believe that the management of TLS should focus on risk assessment, prophylaxis, and treatment [31].”
BackgroundAdmission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients
Thongprayoon, C., Cheungpasitporn, W., Mao, M. A., Sakhuja, A., & Erickson, S. B. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0442-6 · Cited by 53
Li, Q., Cheng, L., Shen, K., Jin, H., Li, H., Cheng, Y., & Ma, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00697 · Cited by 53
“The risk of TLS has relevance with the rapid CLL cells reduction, which can be alleviated by gradual dose escalation therapy (Howard et al., 2011; Souers et al., 2013; King et al., 2017).”
BackgroundEmergencies in haematology: tumour lysis syndrome
Durani, U., & Hogan, W. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16278 · Cited by 53
“Other drugs have also been associated with cases of TLS; these include ibrutinib, lenalidomide, pazopanib, and trastuzumab, among others (Baudon et al., 2016; Cheson et al., 2017; van Kalleveen et al., 2018).”
BackgroundBennet, D., Khorsandian, Y., Pelusi, J., Mirabella, A., Pirrotte, P., & Zenhausern, F. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.461 · Cited by 53
Kataoka, H., Yang, K., & Rock, K. L. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.013 · Cited by 53
“Massive cell death can raise levels of uric acid systemically and cause systemic inflammation, e.g. in tumor lysis syndrome (Howard et al., 2011).”
BackgroundEmergencies in Hematology and Oncology
Halfdanarson, T. R., Hogan, W. J., & Madsen, B. E. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.008 · Cited by 52
“Tumor Lysis Syndrome Tumor lysis syndrome (TLS) is a constellation of metabolic derangements resulting from the death of neoplastic cells which then release their intracellular contents into the circulation.(49) It is most commonly seen in patients with very aggressive hematologic cancers such as high-grade lymphomas…”
BackgroundTumor lysis syndrome in childhood malignancies
Cheung, W. L., Hon, K. E., Fung, C. M., & Leung, A. K. C. (2020) · Drugs in Context · doi:10.7573/dic.2019-8-2 · Cited by 52
Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms
Arnaud, M., Loiselle, M., Vaganay, C., Pons, S., Letavernier, E., Demonchy, J., Fodil, S., Nouacer, M., Placier, S., Frère, P., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070997 · Cited by 52
“Uric-acid nephropathies are also reported during TLS.(1,33) However, the wide use of hypouricemic therapies (90% of the patients in our cohort) has probably decreased the risk of urate nephropathies.”
Backgrounddos Santos, W. T. P., Amin, H. M. A., & Compton, R. G. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.10.037 · Cited by 51
Bansal, D., Davidson, A., Supriyadi, E., Njuguna, F. M., Ribeiro, R. C., & Kaspers, G. J. L. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28087 · Cited by 51
Moghanloo, E., Mollanoori, H., Talebi, M., Pashangzadeh, S., Faraji, F., Hadjilooei, F., & Mahmoodzadeh, H. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101070 · Cited by 49
Abdel-Nabey, M., Chaba, A., Serre, J., Lengliné, É., Azoulay, É., Darmon, M., & Zafrani, L. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-00990-1 · Cited by 48
“TLS occurs due to rapid destruction of tumor cells after cancer chemotherapy initiation, but also spontaneously in one-third of the cases [1, 2].”
BackgroundFindakly, D., Luther, R. D., & Wang, J. (2020) · Cureus · doi:10.7759/cureus.8355 · Cited by 47
“The devastating outcomes of TLS arise from rapid tumor cell lysis and the release of metabolites into the systemic circulation, therefore, leading to potentially fatal metabolic abnormalities, including hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia [1].”
BackgroundInfluentialTrad, R., Warda, W., Alcazer, V., Rocha, M. N. D., Berceanu, A., Nicod, C., Haderbache, R., Roussel, X., Desbrosses, Y., Daguindau, É., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004222 · Cited by 47
CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies
Miller, B. C., & Maus, M. V. (2015) · Oncology Research and Treatment · doi:10.1159/000442170 · Cited by 46
Chantada, G. L., Lam, C. G., & Howard, S. C. (2019) · British Journal of Haematology · doi:10.1111/bjh.15785 · Cited by 46
“Most regimens include a cytoreductive pre-phase, used at the initiation of therapy in order to administer a lower dose of chemotherapy that allows the initial stabilization of the patient and reduces risk of tumour lysis syndrome (TLS) and toxic death (Howard et al, 2011).”
BackgroundSelf-citationAcute kidney injury in cancer patients: A nationwide survey in China
Jin, J., Yf, W., Shen, Q., Gong, J., Zhao, L., & He, Q. (2019) · Scientific Reports · doi:10.1038/s41598-019-39735-9 · Cited by 46
“395 Hospital stay (days) 22 (13,37 23 (13,36) 20 (11,37) 23 (14,37) 21 (11,41) 24 (15,37) 15 (7.”
Wei, A. H., Panayiotidis, P. G., Montesinos, P., Laribi, K., Ivanov, V., Kim, I., Novák, J., Stevens, D. A., Fiedler, W., Pagoni, M. N., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00555-8 · Cited by 46
Vodopivec, D. M., Rubio, J., Fornoni, A., & Lenz, O. (2012) · Case Reports in Medicine · doi:10.1155/2012/468452 · Cited by 46
“Cairo and Bishop definitions of laboratory and clinical TLS are summarized in Table 3 [1–4, 6, 7].”
InfluentialA review in the treatment of oncologic emergencies
Pi, J., Kang, Y. A., Smith, M. C. F., Earl, M. A., Norigian, Z. R., & McBride, A. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215605661 · Cited by 46
“The incidence and severity of TLS depends on numerous factors including tumor mass, type of malignancy, type and intensity of anticancer therapy, high proliferation rate of cancer cells, sensitivity of cancer cells to anticancer therapy, increased lactate dehydrogenase levels, and presence of pre-existing conditions s…”
BackgroundMeng, H., Sun, X., Song, Y., Zou, J., An, G., Jin, Z., & Yang, L. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.04.006 · Cited by 45
Acute kidney injury predicts all‐cause mortality in patients with cancer
Kang, E., Park, M., Park, P. G., Park, N., Jung, Y., Kang, U., Kang, H. G., Kim, D. K., Oh, K., Joo, K. W., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2140 · Cited by 45
Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents
Sun, Z., Zhang, X., Zhao, Z., Li, X., Pang, J., & Chen, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01260 · Cited by 44
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
Bose, P., Dinnel, J., Moore, B. L., & Skiver, B. M. (2015) · Core evidence · doi:10.2147/ce.s54995 · Cited by 44
“Clinically, pre-existing kidney disease, elevated pretreatment uric acid, and volume depletion also predict a higher risk for TLS.”
InfluentialBellal, M., Malherbe, J., Damaj, G. L., & du Cheyron, D. (2024) · Critical Care · doi:10.1186/s13054-024-04851-0 · Cited by 43
“Despite optimal care, severe acute kidney injury (AKI) remains a frequent complication of TLS [27] and may require dialysis according to the AKI guidelines [28].”
Acute Kidney Injury in the Patient with Cancer
Meraz-Muñoz, A., Langote, A., Jhaveri, K. D., Izzedine, H., & Gudsoorkar, P. S. (2021) · Diagnostics · doi:10.3390/diagnostics11040611 · Cited by 42
“Tumor lysis syndrome was defined by Hande-Garrow in 1993 and by Cairo-Bishop in 2004 [77,78], later modified by Howard and colleagues in 2011 [79].”
Enzler, T., Sano, Y., Choo, M.-K., Cottam, H. B., Karin, M., Tsao, H., & Park, J. M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0143 · Cited by 36
“5A, right), a condition reminiscent of tumor lysis syndrome (30).”
Role of transporters in regulating mammalian intracellular inorganic phosphate
Jennings, M. L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1163442 · Cited by 32
“Although [Pi]Ex is normally regulated, hyperphosphatemia is not uncommon and can result from kidney disease, high P intake, hypoparathyroidism, or tumor lysis syndrome (Davidson et al., 2004; Hruska et al., 2008; Howard et al., 2011).”
BackgroundPro-inflammatory effects of uric acid in the gastrointestinal tract
Crane, J. K., & Mongiardo, K. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.864667 · Cited by 39
“Here, we use the term ‘‘uric acid crystals’’ instead of the more chemically accurate name monosodium urate (MSU) crystals, since the former term is already deeply entrenched in the biomedical literature (Howard et al., 2011) and familiar to many readers.”
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
Scheffold, A., & Stilgenbauer, S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0881-4 · Cited by 39
Leukapheresis and Hyperleukocytosis, Past and Future
Zhang, D., Zhu, Y., Jin, Y., Kaweme, N. M., & Dong, Y. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s321787 · Cited by 39
Kaltenmeier, C., Vollmer, L. L., Vernetti, L. A., Caprio, L., Davis, K., Korotchenko, V. N., Day, B. W., Tsang, M., Hulkower, K. I., Lotze, M. T., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239756 · Cited by 39
“BCI-215 caused apoptosis but not primary necrosis, suggesting a physiologic form of cell kill that in clinical settings might avoid the complication of tumor lysis syndrome and the resultant inactivation of immune cells (Howard et al., 2011).”
BackgroundTavassoly, I., Hu, Y., Zhao, S., Mariottini, C., Boran, A. D. W., Chen, Y., Li, L. S. Y., Tolentino, R. E., Jayaraman, G., Goldfarb, J., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12521 · Cited by 39
“Although allopurinol was a not a successful antileukemic drug (Pacher et al., 2006), it has been used successfully to treat gout for over 50 years and is also used to prevent kidney stones associated with hyperuricemia caused by cancer chemotherapy (Howard et al., 2011; Neogi, 2011).”
BackgroundMethodTambaro, F. P., & Wierda, W. G. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30253-4 · Cited by 38
Kanai, T., Uzawa, A., Kawaguchi, N., Oda, F., Ozawa, Y., Himuro, K., & Kuwabara, S. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.10.018 · Cited by 38
Yamauchi, T., Negoro, E., Lee, S., Takai, M., Matsuda, Y., Takagi, K., Kishi, S., Tai, K., Hosono, N., Tasaki, T., et al. (2013) · PubMed · Cited by 38
Cairo, M. S., Thompson, S., Tangirala, K., & Eaddy, M. T. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.003 · Cited by 37
Gribben, J. G. (2019) · British Journal of Haematology · doi:10.1111/bjh.16345 · Cited by 37
“Although it can occur spontaneously, it more commonly occurs after anticancer treatment and is characterised by the rapid lysis of malignant cells and release of their cellular contents into the bloodstream (Howard, 2011).”
BackgroundOncologic Emergencies—The Old, the New, and the Deadly
Thandra, K. C., Salah, Z., & Chawla, S. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618803863 · Cited by 36
“Tumor lysis syndrome is most commonly reported in patients with high-grade non-Hodgkin lymphoma (NHL) and acute leukemias but can also occur during the treatment of large solid tumors (ie, hepatocellular carcinoma, metastatic prostate cancer) that are highly chemosensitive.(19) The pathophysiology is mainly attributed…”
BackgroundStilgenbauer, S., Leblond, V., Foà, R., Böttcher, S., İlhan, O., Knauf, W. U., Mikuskova, E., Renner, C., Tausch, E., Woszczyk, D., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0146-5 · Cited by 36
“rasburicase) prophylaxis for at least 72 h prior to first obinutuzumab dose) for tumor lysis syndrome (TLS) [13], an identified risk in patients treated with obinutuzumab, were included in the protocol from the start.”
BackgroundEvolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
“TLS is a well-recognized phenomenon caused by deposition of malignant cellular components into the bloodstream following lysis, manifesting as rapidly evolving electrolyte derangements with possible life-threatening clinical sequelae [123,124].”
BackgroundGavanier, D., Leport, H., Massardier, J., Abbas‐Chorfa, F., Schott, A., Hajri, T., Golfier, F., & Bolze, P. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1337-9 · Cited by 35
Waggoner, M. S., Katsetos, J., Emilee Thomas, M., Galinsky, I., & Fox, H. R. (2022) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2022.13.4.4 · Cited by 35
“5 × upper limit of normal, cardiac arrhythmia or sudden death, or seizure (Howard et al., 2011).”
BackgroundInfluentialZhang, Q., Zu, C., Jing, R., Feng, Y., Zhang, Y., Zhang, M., Lv, Y., Cui, J., Zhou, L., Meng, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125357 · Cited by 35
Ceppi, F., Antillón‐Klussmann, F., Pacheco, C., Sullivan, C. E., Lam, C. G., Howard, S. C., & Conter, V. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1049594 · Cited by 36
“The best approach for TLS is prevention, and since precipitation of uric acid, calcium phosphate and xanthine causes acute kidney injury in TLS, rapid volume expansion to achieve normal blood pressure and adequate urine output remains the most effective strategy [47].”
BackgroundInfluentialSelf-citationNephrographic and Pyelographic Analysis of CT Urography: Differential Diagnosis
Wolin, E. A., Hartman, D. S., & Olson, J. R. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9692 · Cited by 35
“These electrolyte abnormalities can progress to acute renal insufficiency [14].”
BackgroundOnco-nephrology: current concepts and future perspectives
Kitai, Y., Matsubara, T., & Yanagita, M. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv035 · Cited by 35
“Definitions of laboratory and clinical tumor lysis syndrome (51,52)”
BackgroundWeeks, A. C., & Kimple, M. E. (2015) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709615603199 · Cited by 35
“In contrast to the more inclusive diagnostic criteria proposed by Montesinos and colleagues, Howard and colleagues endorsed more restrictive standards with respect to the laboratory definition.(5) These included both reverting back to the pre–Cairo-Bishop era in recognizing only absolute abnormalities in metabolic der…”
BackgroundResultManaging Tumor Lysis Syndrome in the Era of Novel Cancer Therapies
McBride, A., Trifilio, S. M., Baxter, N., Gregory, T. K., & Howard, S. C. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.7.4 · Cited by 35
“Our recommendation is to tailor the monitoring interval according to the three categories of TLS risk (Table 4), with even more intense monitoring in the event of treatment-emergent clinical TLS (Howard et al., 2011).”
BackgroundMethodInfluentialSelf-citationChhabra, N., & Kennedy, J. M. (2021) · Journal of Medical Toxicology · doi:10.1007/s13181-021-00835-6 · Cited by 34
Małyszko, J., Bamias, A., Danesh, F. R., Dębska-Ślizień, A. M., Gallieni, M. A., Gertz, M. A., Kielstein, J. T., Tesařová, P., Wong, G., Cheung, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.07.012 · Cited by 33
“With the expanded availability of several novel targeted molecular and immune cell–based agents, such as monoclonal antibodies, cyclin-dependent kinase inhibitors, proteasome inhibitors, pro-apoptotic agents, and chimeric antigen receptor (CAR)–T cells, the spectrum of neoplasms with a risk of TLS is expanding and now…”
BackgroundBouclet, F., Calleja, A., Dilhuydy, M., Véronèse, L., Pereira, B., Amorim, S., Cymbalista, F., Herbaux, C., de Guibert, S., Roos‐Weil, D., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04419-w · Cited by 33
“Adverse events of interest were tumor lysis syndrome (TLS) defined according to Howard’s criteria [13] by discerning biological and clinical TLS, infections requiring hospitalization, and the occurrence of autoimmune complications.”
BackgroundMechanisms and strategies for safe chimeric antigen receptor T‐cell activity control
Stock, S., Kluever, A.-K., Fertig, L., Menkhoff, V. D., Subklewe, M., Endres, S., & Kobold, S. (2023) · International Journal of Cancer · doi:10.1002/ijc.34635 · Cited by 32
Supportive Care in Pediatric Oncology
Henry, M., & Sung, L. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.016 · Cited by 32
CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview
Abdalhadi, H., Chatham, W. W., & Alduraibi, F. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910511 · Cited by 31
“Cellular toxicities can be categorized into “on-target-on-tumor”, “on-target-off-tumor” and “off-target” toxicities [127].”
Villas, J. M. C. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2018.10.029 · Cited by 31
Rinaldi, I., Sari, R. M., Tedhy, V. U., & Winston, K. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s312140 · Cited by 30
Management for Electrolytes Disturbances during Continuous Renal Replacement Therapy
Baeg, S. I., Lee, K., Jeon, J., & Jang, H. R. (2022) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2022.20.2.64 · Cited by 30
Gurjanov, A., Kreuchwig, A., Steger‐Hartmann, T., & Vaas, L. A. I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142534 · Cited by 30
“Calcium is known to correlate with phosphate, urea and potassium (Howard et al., 2011; Verzicco et al., 2020), and parathyroid hormone (PTH) (Lecoq et al.”
BackgroundManagement of hematological patients requiring emergency chemotherapy in the intensive care unit
Lafarge, A., Chean, D., Whiting, L., Clère-Jehl, R., (GRRR-OH), G. D. R. E. R. R. D. P. D.-H., Azoulay, É., Mokart, D., Lemiale, V., Argaud, L., Benoît, D., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07454-z · Cited by 30
Risi, G., Bloise, N., Merli, D., Cornaglia, A. I., Profumo, A., Fagnoni, M., Quartarone, E., Imbriani, M., & Visai, L. (2014) · RSC Advances · doi:10.1039/c4ra02366h · Cited by 30
The Safety of available immunotherapy for the treatment of glioblastoma
Farber, S. H., Elsamadicy, A. A., Atik, A. F., Suryadevara, C. M., Chongsathidkiet, P., Fecci, P. E., & Sampson, J. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1273898 · Cited by 30
“TLS is associated with tumor cells releasing their contents into the bloodstream ensuing severe electrolyte abnormalities, such as hyperkalemia, hyperphosphatemia, and hypocalcemia [57].”
BackgroundUnderstanding tumor lysis syndrome
Zafrani, L., Canet, E., & Darmon, M. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05768-x · Cited by 30
Lasko, T. A., Denny, J. C., & Levy, M. A. (2013) · PLoS ONE · doi:10.1371/annotation/0c88e0d5-dade-4376-8ee1-49ed4ff238e2 · Cited by 30
Bociek, R. G., & Lunning, M. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2300923 · Cited by 29
Herrington, J. D., & Dinh, B. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214520821 · Cited by 29
“Email: jherrington@sw.org increase nephrotoxicity from calcium and phosphate precipitation and/or xanthine or hypoxanthine precipitation in the renal tubules.2 Allopurinol traditionally has been used in patients with or at risk of hyperuricemia from TLS. Allopurinol, an analog of the purine base hypoxanthine, can be u…”
BackgroundInfluentialSpring, J. L., & Munshi, L. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2020.08.004 · Cited by 29
Renaghan, A. D., Ostermann, M., Ronco, C., Ballen, K. K., Cosmai, L., Fenoglio, R., Floris, M., Forni, L. G., Gladstone, D. E., Glezerman, I. G., et al. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01031-3 · Cited by 28
Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review
Khan, I., Khan, N., Wolfson, N., Djebabria, K., Rehman, M. E. U., & Anwer, F. (2023) · Clinical Hematology International · doi:10.1007/s44228-023-00037-7 · Cited by 28
Pediatric Hematology-Oncology in Countries with Limited Resources: A Practical Manual
Stefan, D. C., & Galindo, C. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3891-5 · Cited by 29
Oncologic Metabolic Emergencies
Wagner, J. G., & Arora, S. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.08.002 · Cited by 28
Gershkovich, B., Fernando, S. M., Herritt, B., Castellucci, L. A., Rochwerg, B. N., Munshi, L., Mehta, S., SEELY, A. J. E., McIsaac, D. I., Tran, A., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2568-5 · Cited by 28
Ikemura, K., Hiramatsu, S., Shinogi, Y., Nakatani, Y., Tawara, I., Iwamoto, T., Katayama, N., & Okuda, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56900-2 · Cited by 28
Metadata
- Authors
- Howard, S. C., Jones, D. P., & Pui, C.-H.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-12
- Volume
- 364
- Issue
- 19
- Pages
- 1844-1854
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3437249
- OpenAlex
- W2122479144
- Cited by
- 1,044
- References
- 58
- Citations by year
- 2026: 71 · 2025: 67 · 2024: 86 · 2023: 71 · 2022: 69 · 2021: 81 · 2020: 89 · 2019: 154 · 2018: 60 · 2017: 53 · 2016: 49 · 2015: 57 · 2014: 47 · 2013: 49 · 2012: 31
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA21765, P30CA021765)
- National Institute of General Medical Sciences (U01GM92666, U01GM092666)
- Topics
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Keywords
- tumor lysis syndrome, hematologic malignancies, risk assessment, prophylaxis, treatment, pediatric oncology, emergency management
- MeSH terms
- Child, Humans, Male, Tumor Lysis Syndrome, Risk Assessment, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.